Independent directory Public ClinicalTrials.gov records United States
Clear filters
ClinicalTrials.gov public records Last synced Sep 28, 2026, 7:25 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 45 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Conditions
Diabetes Mellitus, Type 1
Interventions
SGLT2 inhibitor, Biosense Breath Ketone Analyzer
Drug · Device
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years to 75 Years
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
1
States / cities
St Louis, Missouri
Conditions
Diabetes Mellitus, Type 2
Interventions
Dapagliflozin 10mg then Placebo Oral Tablet, Placebo Oral Tablet then Dapagliflozin 10mg
Drug
Lead sponsor
The University of Texas Health Science Center at San Antonio
Other
Eligibility
18 Years to 70 Years
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
1
States / cities
San Antonio, Texas
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Drug Interaction Study of Saxagliptin in Combination With Dapagliflozin in Healthy Participants

NCT01662999
Conditions
Type 2 Diabetes Mellitus
Interventions
Saxagliptin, Dapagliflozin
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 45 Years
Enrollment
42 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012
U.S. locations
1
States / cities
Omaha, Nebraska
Completed No phase listed Observational

OPTIMISE-CKD Drug Utilization

NCT05932901
Conditions
Chronic Kidney Disease
Interventions
Not listed
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 130 Years
Enrollment
2,682,052 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
1
States / cities
Minneota, Minnesota
Conditions
Diabetes Mellitus, Type 2, Cardiovascular Diseases
Interventions
Dapagliflozin 10mg, Saxagliptin 5mg, Placebo Oral Tablet
Drug
Lead sponsor
Sabyasachi Sen
Other
Eligibility
30 Years to 70 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Completed Not applicable Interventional Results available

ESR-15-11293 - Saxa/Dapa, Safety and Efficacy Study

NCT02613897
Conditions
Diabetes Mellitus, Type 2
Interventions
Saxagliptin, Dapagliflozin, Placebo
Drug
Lead sponsor
The University of Texas Health Science Center at San Antonio
Other
Eligibility
18 Years to 70 Years
Enrollment
56 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
1
States / cities
San Antonio, Texas
Conditions
Chronic Kidney Disease, Type 2 Diabetes
Interventions
Finerenone, Semaglutide, Lotensin, Capoten, Enalapril, Monopril, Lisinopril, Univasc, Aceon, Accupril, Altace, Mavik, Edarbi, Atacand, Avapro, Cozaar, Benicar, Micardis, Diovan, Invokana, Farxiga, Jardiance, Ertugliflozin, Brenzavvy, Sotagliflozin
Drug
Lead sponsor
Baylor Research Institute
Other
Eligibility
18 Years to 84 Years
Enrollment
64 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
1
States / cities
Temple, Texas
Conditions
Type 2 Diabetes
Interventions
Dapagliflozin, Placebo
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 80 Years
Enrollment
1,240 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
13
States / cities
Fresno, California • Greenbrae, California • Roswell, Georgia + 10 more
Conditions
Fontan Circulation, Single Ventricle Heart Disease, HFpEF - Heart Failure With Preserved Ejection Fraction
Interventions
Dapagliflozin tablet, Placebo Tablet
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Rochester, Minnesota
Conditions
Type1diabetes
Interventions
Dapagliflozin 10mg Tab, Pioglitazone 15 MG and 30mg, Placebo
Drug · Other
Lead sponsor
The University of Texas Health Science Center at San Antonio
Other
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
San Antonio, Texas
Conditions
Evaluate Ketogenic Stress
Interventions
Exenatide/Exenatide extended release, Dapagliflozin, Placebo
Drug
Lead sponsor
University at Buffalo
Other
Eligibility
18 Years to 65 Years
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2021
U.S. locations
1
States / cities
Williamsville, New York
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Effect of Dapagliflozin on Hepatic and Renal Glucose Metabolism Subjects

NCT02981966
Conditions
Diabetes Mellitus, Type 2
Interventions
Dapagliflozin, Placebo
Drug
Lead sponsor
The University of Texas Health Science Center at San Antonio
Other
Eligibility
18 Years to 70 Years
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2023
U.S. locations
1
States / cities
San Antonio, Texas
Conditions
Diabetes Mellitus, Type 2
Interventions
Dapagliflozin, Saxagliptin, Placebo
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
10 Years to 18 Years
Enrollment
256 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2024
U.S. locations
20
States / cities
Sacramento, California • New Haven, Connecticut • Hialeah, Florida + 12 more
Conditions
Type 1 Diabetes
Interventions
Dapagliflozin 10 MG [Farxiga], REMD-477, Placebo
Drug
Lead sponsor
University of California, San Diego
Other
Eligibility
18 Years to 65 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
La Jolla, California
Conditions
Breast Cancer, Hyperinsulinism, HER2-negative Breast Cancer
Interventions
Dapagliflozin 10mg
Drug
Lead sponsor
Yale University
Other
Eligibility
18 Years and older · Female only
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
1
States / cities
New Haven, Connecticut
Conditions
Heart Failure, Acute Kidney Injury
Interventions
Dapagliflozin 10mg Tab, Placebo
Drug
Lead sponsor
Yale University
Other
Eligibility
18 Years to 85 Years
Enrollment
130 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2029
U.S. locations
2
States / cities
New Haven, Connecticut
Conditions
Chronic Heart Failure With Preserved Systolic Function
Interventions
Dapagliflozin 10Mg Oral Tablet, Dapagliflozin matching placebo
Drug
Lead sponsor
Saint Luke's Health System
Other
Eligibility
19 Years to 119 Years
Enrollment
324 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
26
States / cities
Fairhope, Alabama • Los Angeles, California • Jacksonville, Florida + 21 more
Conditions
Diabetes Mellitus, Type 2
Interventions
Dapagliflozin, Exenatide, Placebo
Drug
Lead sponsor
The University of Texas Health Science Center at San Antonio
Other
Eligibility
18 Years to 70 Years
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2023
U.S. locations
1
States / cities
San Antonio, Texas
Conditions
Type 2 Diabetes
Interventions
Dapagliflozin, Dapagliflozin placebo
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
10 Years to 24 Years
Enrollment
72 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
15
States / cities
New Haven, Connecticut • Washington D.C., District of Columbia • Gainesville, Florida + 11 more
Conditions
Type II; Diabetes
Interventions
Dapagliflozin, Placebo
Drug
Lead sponsor
The University of Texas Health Science Center at San Antonio
Other
Eligibility
18 Years to 70 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
San Antonio, Texas
Conditions
Type 2 Diabetes Mellitus, CKD and Albuminuria
Interventions
Dapagliflozin 10 mg, Saxagliptin 2.5 mg, Matching Placebo for Dapagliflozin 10 mg and Saxagliptin 2.5mg
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 130 Years
Enrollment
459 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
37
States / cities
Peoria, Arizona • Chula Vista, California • Concord, California + 34 more
Conditions
Type II Diabetes
Interventions
Farxiga, Placebo, Metformin, Insulin
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 75 Years
Enrollment
226 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015
U.S. locations
26
States / cities
Birmingham, Alabama • Phoenix, Arizona • Huntington Park, California + 23 more
Conditions
Heart Failure, Sleep Disordered Breathing
Interventions
Dapagliflozin, WatchPat
Drug · Device
Lead sponsor
Columbia University
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
1
States / cities
New York, New York
Conditions
Type II Diabetes Mellitus
Interventions
Dapagliflozin, Placebo
Drug
Lead sponsor
The University of Texas Health Science Center at San Antonio
Other
Eligibility
18 Years to 70 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
1
States / cities
San Antonio, Texas